Last reviewed · How we verify
Placebo to match BTDS
This drug is a placebo that matches BTDS, meaning it has no active pharmacological effect.
This drug is a placebo that matches BTDS, meaning it has no active pharmacological effect. Used for Matching placebo for BTDS clinical trials.
At a glance
| Generic name | Placebo to match BTDS |
|---|---|
| Sponsor | Purdue Pharma LP |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems, and its effects are purely psychological or due to the natural course of the disease being studied.
Approved indications
- Matching placebo for BTDS clinical trials
Common side effects
Key clinical trials
- The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) at Doses up to 80 Micrograms/Hour (mcg/hr) and Naltrexone on Electrocardiogram (ECG) Intervals in Healthy Volunteers (PHASE1)
- Buprenorphine Accumulation and Description of Its Metabolites During Co-Medication of Buprenorphine Transdermal System (BTDS) and Ketoconazole (PHASE1)
- Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee (PHASE3)
- Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Chronic Nonmalignant Pain (PHASE3)
- Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain (PHASE3)
- Safety of Buprenorphine Transdermal System (BTDS) in Subjects With Acute Postoperative Pain After Total Knee Replacement (PHASE2)
- Buprenorphine Transdermal Patch in Subjects With Osteoarthritis Pain Requiring Opioids. Includes a 52-Week Safety Extension. (PHASE3)
- The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to match BTDS CI brief — competitive landscape report
- Placebo to match BTDS updates RSS · CI watch RSS
- Purdue Pharma LP portfolio CI